SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Discovery Labs: The Next Biotech Winner?
DNA
|
|
|
<> I think the recent decline in Discovery Labs (DSCO) since the Company announced a minor delay in submitting a complete response to the FDA for an approvable ruling on Surfaxin represents a buying opportunity and bought some shares on Friday at $1.74 per share. Insider buying over the past two months (including a 75,000 share buy from the CEO at $1.87) demonstrates management's confidence in already meeting the FDA's requirements and the plan to submit a complete response to FDA for Surfaxin, which should now occur by about the third ...
|
Bullish on DNA ...
DNA
|
|
|
<> <> <> <> Genentech Inc, (DNA) Genentech, Inc. engages in the discovery, development, manufacture, and commercialization of biotherapeutics in the United States. It markets Avastin (bevacizumab) for treating metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer. The company also commercializes Rituxan (rituximab) to treat B-cell non-Hodgkin's lymphoma; Herceptin (trastuzumab) for treating node-positive breast cancer; and Lucentis (ranibizumab) to treat neovascular (wet) age-related macular degeneration. ...
|
DNA
DNA
|
|
|
Exclusive short term trade
|
Bullish on DNA ...
DNA
|
|
|
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $83 Analysts' Targets Deutsche Bank Securities $83 Accumulate Thursday, June 19, 2008 RBC Capital Markets $84 Outperform Monday, February 25, 2008 Jefferies & Co. $78 Accumulate Monday, February 25, 2008 Lazard Capital Markets $87 Strong Buy Monday, February 25, 2008 Lehman Brothers $70 Equalweight Monday, February 25, 2008 Friedman, Billings, Ramsey & C $76 Hold Monday, February 25, 2008 UBS Securities $95 Add ...
|
S&P Fair Value :$93.80
DNA
|
|
|
Per the S&P: <> Although we consider DNA a core biotechnology holding, we see the shares as appropriately valued, given slowing growth trends across the product portfolio.We see recent FDA accelerated Avastin approval in metastatic breast cancer supporting the shares, preserving prior offlabel prescribing, and expect full approval as new studies confirm progression-free survival trends.We remain positive on DNA's long-term pipeline, with 15 new compounds entering clinical study in the first two years of a five-year, 30 new compound goal, and see DNA well positioned to benefit from robust f...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Trader who needs HELP!!
- Im looking for a Stock Pick Website. What are the most important things for me to look for? What makes a good Stock Pick site? What sort of content sho
|
More Resources
|
About Genentech Inc
- Answers.com
